Trade AbbVie

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a benefit from Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate two public lycies. Abbott's new laboratories will specialize in various products including medical devices, diagnostic equipment and nutrition products, while research-based pharmaceutical company AbbVie will work. The chapter was in effect on January 1, 2013, and AbbVie was officially listed on the New York Stock Exchange (ABBV) on January 2, 2013. Some investors expressed concern that this split had been made to protect the value of the device's business from the loss of value faced by the pharmaceutical division due to the near expiry of the patents on Humera, which accounted for about half of the drug division's revenue. As of December 2015, the company has employed more than 28,000 worldwide and provided products to individuals in more than 170 countries. In March 2020, as the COVID-19 pandemic developed into an international crisis, the Israeli government announced that it would force AbbVie to license its patents to Kaletra, the trade name for lopinavir/ritonavir, a fixed dose of combination drugs for the treatment and prevention of HIV/AIDS, which was also thought to have some applicability to fight COVID-19. In response, AbbVie announced that it would stop enforcing its patents on the drug in full.